Himalaya Nutravedics India IPO
Himalaya Nutravedics India IPO Details
-
Open Date
22 Sep 2026
-
Close Date
24 Sep 2026
- IPO Price Range
₹ 100 to ₹106
- IPO Size
₹ 26.50 Cr
Himalaya Nutravedics India IPO Timeline
Last Updated: 17 September 2026 11:28 AM by 5paisa
Himalaya Nutravedics India Limited manufactures, markets and distributes Ayurvedic and nutraceutical formulations in India. Its portfolio includes classical or Shastric Ayurvedic formulations, proprietary Ayurvedic products and nutraceuticals across dosage forms such as soft gelatin capsules, hard gelatin capsules, tablets, liquid orals and medicated oils.
The company follows a hybrid business model comprising its own branded products and third-party contract manufacturing for other Ayurvedic and nutraceutical companies. Its products address therapeutic and wellness categories including digestive health, cardiac and metabolic wellness, diabetes management, pain management, immunity, women's health and general wellness.
Manufacturing operations are carried out from its facility at Cherlapally, Hyderabad. The company has developed a distribution network across multiple Indian states and markets its products through stockists and an on-ground sales and medical-representative network. Its manufacturing and product operations are subject to regulatory frameworks including AYUSH and FSSAI requirements.
Established in: 2022
Managing Director: Rohit Asawa
Peers:
Sandu Pharmaceuticals Limited
Jeena Sikho Lifecare Limited
Himalaya Nutravedics India Objectives
1. Funding working capital requirements
2. Funding business development and digital marketing activities
3. General corporate purposes
The company proposes to deploy approximately ₹13.75 crore towards working capital requirements and ₹7.50 crore towards business development and digital marketing activities, with the balance Net Proceeds proposed for general corporate purposes.
Himalaya Nutravedics India IPO Size
| Types | Size |
|---|---|
| Total IPO Size | ₹26.50 Cr |
| Offer For Sale | - |
| Fresh Issue | ₹26.50 Cr |
Himalaya Nutravedics India IPO Lot Size
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 2 | 2,400 | 2,40,000 |
| Retail (Max) | 2 | 2,400 | 2,54,400 |
| S-HNI (Min) | 3 | 3,600 | 3,60,000 |
| S-HNI (Max) | 7 | 8,400 | 8,90,400 |
| B-HNI (Min) | 8 | 9,600 | 10,17,600 |
| Particulars (In ₹ Crores) | FY24 | FY25 | FY26 |
| Revenue | 14.42 | 20.99 | 43.06 |
| EBITDA | 0.94 | 2.99 | 8.10 |
| PAT | 0.43 | 2.23 | 7.39 |
| Particulars (In ₹ Crores) | FY24 | FY25 | FY26 |
| Total Assets | 6.09 | 10.82 | 24.42 |
| Share Capital | 0.83 | 4.00 | 6.31 |
| Total Liabilities | 4.75 | 4.07 | 8.04 |
| Particulars (In ₹Crores.) | FY24 | FY25 | FY26 |
| Net Cash Generated From / (used in) Operating Activities | (0.55) | (1.39) | (3.83) |
| Net Cash Generated From / (used in) Investing Activities | (1.10) | (0.23) | (0.06) |
| Net Cash Generated From / (used in) Financing Activities | 1.84 | 1.44 | 5.27 |
| Net Increase (Decrease) in Cash and Cash Equivalents | 0.19 | (0.18) | 1.38 |
Strengths
1. The company has integrated manufacturing capabilities across multiple dosage forms, including capsules, tablets, liquid formulations and medicated oils.
2. Its business model combines own-brand Ayurvedic and nutraceutical products with third-party contract manufacturing, providing multiple revenue channels.
3. The product portfolio spans several therapeutic and wellness categories, including digestive health, metabolic wellness, immunity, pain management and women's health.
4. Himalaya Nutravedics has expanded its distribution footprint across multiple Indian states within a relatively short operating history.
5. Revenue increased from ₹14.42 crore in FY24 to ₹43.06 crore in FY26, accompanied by growth in EBITDA and PAT margins.
Weaknesses
1. Ayurvedic products contributed approximately 94.57% of revenue from operations in FY26, resulting in significant dependence on a single broad product category.
2. A substantial portion of revenue is derived from certain key customers, exposing the company to customer-concentration risk.
3. Procurement is dependent on a relatively concentrated group of suppliers, including its top 10 suppliers.
4. The company operates from a single manufacturing facility in Hyderabad, creating operational concentration risk.
5. Operating cash flows were negative in FY24, FY25 and FY26 despite the company's reported profitability.
Opportunities
1. Growing consumer preference for preventive healthcare, wellness products and natural formulations can support demand for Ayurvedic and nutraceutical products.
2. The company's planned expenditure on business development and digital marketing could increase the reach of its own-brand portfolio.
3. Expansion of its stockist-driven network into additional territories can broaden its domestic market presence.
4. Its contract-manufacturing capabilities provide scope to serve additional Ayurvedic and nutraceutical brands without relying solely on its own products.
5. Expansion into additional therapeutic categories and dosage forms can broaden the company's addressable product portfolio.
Threats
1. The Ayurvedic and nutraceutical industry is subject to regulatory requirements relating to product approvals, manufacturing standards, labelling and food or medicinal claims.
2. Failure to maintain required quality standards at its sole manufacturing facility could affect production, customer relationships and regulatory compliance.
3. Competition from established Ayurvedic, pharmaceutical, wellness and nutraceutical brands may put pressure on pricing and market expansion.
4. Dependence on key suppliers exposes operations to raw-material availability, quality and price volatility.
5. Changes in consumer preferences or adverse developments affecting confidence in Ayurvedic and nutraceutical products could affect demand.
1. Revenue from operations increased from ₹14.42 crore in FY24 to ₹43.06 crore in FY26, while PAT rose from ₹0.43 crore to ₹7.39 crore.
2. EBITDA margin improved to approximately 18.81% in FY26 from around 14.24% in FY25.
3. The business combines proprietary and classical Ayurvedic products, nutraceutical products and third-party contract manufacturing across multiple dosage forms.
4. Its distribution network spans multiple Indian states and is supported by a stockist-driven model and on-ground sales organisation.
5. The fresh issue is intended primarily to fund working capital requirements and business development and digital marketing activities, supporting the company's expansion plans.
India's Ayurvedic and nutraceutical industry forms part of the broader healthcare and wellness ecosystem, covering traditional Ayurvedic medicines, herbal formulations, dietary supplements, functional products and other preventive-health offerings. Demand is being supported by greater awareness of preventive healthcare, lifestyle-related health conditions and consumer interest in natural and wellness-oriented products.
The sector also operates within established regulatory frameworks, including requirements administered by the Ministry of AYUSH and FSSAI depending on product classification. Manufacturing capability, formulation expertise, product quality and compliance therefore remain important competitive factors.
Himalaya Nutravedics participates in this market through both its own-brand portfolio and third-party manufacturing. Its products span Ayurvedic and nutraceutical formulations across several dosage forms and therapeutic categories. The company has developed a distribution footprint across multiple states and uses a stockist-led network supported by medical representatives and other sales personnel. Proposed IPO spending on working capital, business development and digital marketing is intended to support the next phase of business expansion.
- Companies
- Type
- Opening On
-
Varmora Granito
- Mainboard
- 22nd Sep
- Pre-Book
Open Free Demat Account
Be a part of 5paisa community - The first listed discount broker of India.
By proceeding, you agree to all T&C*
FAQs
Himalaya Nutravedics India IPO opens on 22 September 2026 and closes on 24 September 2026.
The size of the Himalaya Nutravedics India IPO is approximately ₹26.50 crore at the upper end of the price band. The issue consists entirely of a fresh issue of up to 25,00,000 equity shares.
The price band of Himalaya Nutravedics India IPO is fixed at ₹100 to ₹106 per share.
1. Login to your 5paisa demat account and select the issue in the current IPO section.
2. Enter the number of lots and the price at which you wish to apply for the Himalaya Nutravedics India IPO.
3. Enter your UPI ID and click on submit. Your bid will then be placed with the exchange.
4. You will receive a mandate notification to block funds in your UPI app.
The minimum application size is 2,400 shares, equivalent to two lots of 1,200 shares each. At the floor price of ₹100 per share, the minimum investment is ₹2,40,000.
The basis of allotment for the Himalaya Nutravedics India IPO is expected to be finalised on 25 September 2026.
The Himalaya Nutravedics India IPO is tentatively scheduled to list on BSE SME on 29 September 2026.
Nirbhay Capital Services Private Limited is the book-running lead manager for the Himalaya Nutravedics India IPO.
The company proposes to utilise the Net Proceeds from the fresh issue towards:
1. Funding working capital requirements
2. Funding business development and digital marketing activities
3. General corporate purposes